← Oncology Approval Tracker

FDA DECISION ·

Calquence tablets

acalabrutinib maleate · AstraZeneca

FDA approvalNew formulationMantle cell lymphoma, chronic lymphocytic leukemia and small lymphocytic lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

The tablet formulation for adults with CLL or SLL, or mantle cell lymphoma after at least one prior therapy, as specified on its original label.

LAMPGEN ANALYSIS

Why it matters

The tablet gives a different oral presentation for existing acalabrutinib indications.

What research teams should watch

Document tablet versus capsule in medication reconciliation and check formulation-specific coadministration instructions.

PRIMARY RECORDS

Sources